High-intensity statin therapy
High-intensity statin therapy has been studied in 4 papers since 2025: 4 observational studies in people; 3 in the past year. The newest paper, Jun 10, 2026: “Age-dependent associations of high-intensity statin therapy with 3-year clinical outcomes after acute myocardial infarction: longitudinal LDL-C profiles in a nationwide registry”.
4 papers study it6 findingsUpdated
“There was no significant difference in major cardiovascular events (MACE) between the two statin intensity groups (HR = 1.13, 95% CI: 0.92–1.38, p = 0.249).”
1 of its findings points the other way.
- 3 independent labs in 1 country
- 1 finding against
- Funders: Korea Health Industry Development Institute and 2 more
- Humans4
What did studies of High-intensity statin therapy find?
5Studies of High-intensity statin therapy measured 5 outcomes; the most studied are major adverse cardiovascular events (1 study), stroke recurrence (1) and modified Rankin Scale (1).
Major adverse cardiovascular events
no changein humans1
1 study
Major adverse cardiovascular events
no changein humans1
High-intensity statin therapy was not clearly linked with major adverse cardiovascular events in humans (age ≥75 years).
“In patients aged ≥ 75 years, neither composite outcome showed a statistically evident association with statin intensity.”
Humansage ≥75 yearshigh-intensity3 yearsn = 1,831
BMC cardiovascular disorders
Stroke recurrence
no changein humans1
1 study
Stroke recurrence
no changein humans1
High-intensity statin therapy was not clearly linked with stroke recurrence in humans (compared with moderate-intensity statin therapy in older patients).
“No significant differences were observed in statin discontinuation, stroke recurrence, or adverse effects.”
Humanscompared with moderate-intensity statin therapy in older patients3 monthsn = 337
Annals of geriatric medicine and research
Modified Rankin Scale
upin humans1
1 study
Modified Rankin Scale
upin humans1
High-intensity statin therapy is linked with better modified Rankin Scale in humans (aOR 2.03, 95% CI 1.17-3.53).
“After multivariable adjustment, HIST was independently associated with a favorable outcome (adjusted odds ratio [aOR]=2.03, 95% confidence interval [CI] 1.17-3.53)”
Humanspatients aged ≥75 years with acute ischemic stroke or transient ischemic attack vs moderate-intensity statin therapy3 monthsn = 337
Annals of geriatric medicine and research
Mortality
downin humans1HR 0.77
1 study
Mortality
downin humans1HR 0.77
High-intensity statin therapy is linked with lower mortality in humans (ischemic stroke, baseline LDL-C ≥100 mg/dL) (HR 0.77, 95% CI 0.60–0.98, p = 0.037).
“However, in patients with baseline LDL-C ≥100 mg/dL, high-intensity statin therapy was associated with a significant reduction in all-cause mortality (HR = 0.77, 95% CI: 0.60–0.98, p = 0.037).”
Humansischemic stroke, baseline LDL-C ≥100 mg/dL
ENDO 2025 abstract
Major cardiovascular events
no changein humans1HR 1.13
1 study
Major cardiovascular events
no changein humans1HR 1.13
High-intensity statin therapy was not clearly linked with major cardiovascular events in humans (ischemic stroke, statin-naïve) (HR 1.13, 95% CI 0.92–1.38, p = 0.249).
“There was no significant difference in major cardiovascular events (MACE) between the two statin intensity groups (HR = 1.13, 95% CI: 0.92–1.38, p = 0.249).”
Humansischemic stroke, statin-naïven = 4,293
ENDO 2025 abstract
What is High-intensity statin therapy linked with?
1Studies link High-intensity statin therapy with 1 measure, most often major adverse cardiovascular events (1 study).
Major adverse cardiovascular events
downin humans1HR 0.69
1 study
Major adverse cardiovascular events
downin humans1HR 0.69
High-intensity statin therapy is linked with a lower risk of major adverse cardiovascular events in humans (age 65-74 years, overall cohort) (13.6% vs. 18.9%; adjusted HR 0.69 (95% CI 0.55-0.87)).
“high-intensity statins were associated with lower risks of MACE (overall cohort: 13.6% vs. 18.9%, adjusted HR 0.69, 95% CI 0.55-0.87, p < 0.01”
Humansage 65-74 years, overall cohorthigh-intensity3 yearsn = 2,316
BMC cardiovascular disorders